The firm is a U.S.-based venture capital investor with venture studio capabilities, focused primarily on Pre-Seed and Seed-stage companies. The firm typically makes initial investments ranging from $250K–$500K and is flexible in its investment structures, including lending and co-investment arrangements. The firm takes an active approach to supporting early-stage companies through concept validation, clinical development, regulatory planning, and reimbursement strategy. The firm primarily targets opportunities in the United States, particularly in established innovation ecosystems, while remaining open to international companies with potential for U.S. expansion.
The firm invests across digital therapeutics, diagnostics, and medical devices, with particular interest in cardiovascular diseases, metabolic disorders, diabetes, nephropathy, and women’s health. The firm prefers to engage with companies at the earliest stages of commercialization and generally seeks technologies that have reached at least the minimum viable product stage. The firm places particular emphasis on opportunities where additional clinical, technical, or commercial evidence can meaningfully advance product development and market readiness.
From a company and management team perspective, the firm does not impose specific requirements regarding founding team composition or prior entrepreneurial experience. The firm prefers U.S.-based companies or international businesses with a willingness or incentive to establish operations in the United States. The firm provides hands-on support in gathering product validation data, navigating clinical trials, and addressing regulatory and reimbursement requirements. The firm may seek board observer rights on a case-by-case basis.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
